B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $41

Benzinga Newsdesk www.benzinga.com Negative 51.7%

Neg 51.7% Neu 0% Pos 0%

B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $44 to $41.